Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Fairmount Funds Management LLC

2. Date of Event Requiring Statement (MM/DD/YYYY) 10/27/2020

3. Issuer Name and Ticker or Trading Symbol

MIRAGEN THERAPEUTICS, INC. [MGEN]

(Last) (First) (Middle)

2001 MARKET STREET, SUITE 2500

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director _____ 10% Owner
_____ Officer (give title below) ___X___ Other (specify below)
/ See Remarks

(Street)

PHILADELPHIA, PA 19103

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	526393	I	By funds ⁽¹⁾⁽²⁾

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series A Non-Voting Convertible Preferred Stock	⁽³⁾	⁽³⁾	Common Stock	131191000	⁽³⁾	I	By funds ⁽²⁾⁽⁴⁾

Explanation of Responses:
(1)	Consists of (i) 87,891 shares owned by Fairmount Healthcare Fund LP ("Fund I"); and (ii) 438,502 shares owned by Fairmount Healthcare Fund II LP ("Fund II").
(2)	Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
(3)	Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.
(4)	Consists of (i) 21,999,000 shares of common stock issuable upon the conversion of 21,999 shares of Series A Non-Voting Convertible Preferred Stock owned by Fund I; and (ii) 111,192,000 shares of common stock issuable upon the conversion of 111,192 shares of Series A Non-Voting Convertible Preferred Stock owned by Fund II.

Remarks:
Exhibit 24 - Power of Attorney

The Reporting Persons may each be deemed a director by deputization of Issuer by virtue of the fact that each of Peter Harwin and Tomas Kiselak serve on the board of directors of Issuer and are also each a Managing Member of Fairmount Funds Management LLC.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Fairmount Funds Management LLC 2001 MARKET STREET, SUITE 2500 PHILADELPHIA, PA 19103	X			See Remarks
Fairmount Healthcare Fund GP LLC 2001 MARKET STREET, SUITE 2500 PHILADELPHIA, PA 19103	X			See Remarks
Fairmount Healthcare Fund II GP LLC 2001 MARKET STREET, SUITE 2500 PHILADELPHIA, PA 19103	X			See Remarks
Fairmount Healthcare Fund L.P. 2001 MARKET STREET, SUITE 2500 PHILADELPHIA, PA 19103	X			See Remarks
Fairmount Healthcare Fund II L.P. 2001 MARKET STREET, SUITE 2500 PHILADELPHIA, PA 19103	X			See Remarks

Signatures
/s/ Chris W. Trester, Attorney-in-fact for Fairmount Funds Management LLC		10/30/2020
^**Signature of Reporting Person		Date
/s/ Chris W. Trester, Attorney-in-fact for Fairmount Healthcare Fund GP LLC		10/30/2020
^**Signature of Reporting Person		Date
/s/ Chris W. Trester, Attorney-in-fact for Fairmount Healthcare Fund II GP LLC		10/30/2020
^**Signature of Reporting Person		Date
/s/ Chris W. Trester, Attorney-in-fact for Fairmount Healthcare Fund LP		10/30/2020
^**Signature of Reporting Person		Date
/s/ Chris W. Trester, Attorney-in-fact for Fairmount Healthcare Fund II LP		10/30/2020
^**Signature of Reporting Person		Date